Long-Term Biodistribution and Safety of Human Dystrophin Expressing Chimeric Cell Therapy After Systemic-Intraosseous Administration to Duchenne Muscular Dystrophy Model
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1661-4917
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Long-Term Biodistribution and Safety of Human Dystrophin Expressing Chimeric Cell Therapy After Systemic-Intraosseous Administration to Duchenne Muscular Dystrophy Model ; volume:70 ; number:1 ; day:17 ; month:8 ; year:2022 ; pages:1-15 ; date:12.2022
Archivum immunologiae et therapiae experimentalis ; 70, Heft 1 (17.8.2022), 1-15, 12.2022
- Creator
-
Siemionow, Maria
Brodowska, Sonia
Langa, Paulina
Zalants, Kristina
Kozlowska, Katarzyna
Grau-Kazmierczak, Wictoria
Heydemann, Ahlke
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s00005-022-00656-7
- URN
-
urn:nbn:de:101:1-2022110421441617938468
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:22 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Siemionow, Maria
- Brodowska, Sonia
- Langa, Paulina
- Zalants, Kristina
- Kozlowska, Katarzyna
- Grau-Kazmierczak, Wictoria
- Heydemann, Ahlke
- SpringerLink (Online service)
Other Objects (12)
Dystrophin Expressing Chimeric (DEC) Human Cells Provide a Potential Therapy for Duchenne Muscular Dystrophy
Dystrophin bei Muskeldystrophie vom Typ Duchenne und Becker-Kiener
Dystrophin Dp71 and the Neuropathophysiology of Duchenne Muscular Dystrophy
Creation of Dystrophin Expressing Chimeric Cells of Myoblast Origin as a Novel Stem Cell Based Therapy for Duchenne Muscular Dystrophy
Cardiac Protection after Systemic Transplant of Dystrophin Expressing Chimeric (DEC) Cells to the mdx Mouse Model of Duchenne Muscular Dystrophy
Dystrophin Expressing Chimeric (DEC) Cell Therapy for Duchenne Muscular Dystrophy: A First-in-Human Study with Minimum 6 Months Follow-up
Dual exon skipping in myostatin and dystrophin for Duchenne muscular dystrophy
Systemic delivery of full-length dystrophin in Duchenne muscular dystrophy mice
Dystrophin and mini-dystrophin quantification by mass spectrometry in skeletal muscle for gene therapy development in Duchenne muscular dystrophy
Adenine base editing-mediated exon skipping restores dystrophin in humanized Duchenne mouse model
Long-Term Protective Effect of Human Dystrophin Expressing Chimeric (DEC) Cell Therapy on Amelioration of Function of Cardiac, Respiratory and Skeletal Muscles in Duchenne Muscular Dystrophy
Deletion pattern in the dystrophin gene in Duchenne muscular dystrophy patients in northeast India
Dystrophin Expressing Chimeric (DEC) Human Cells Provide a Potential Therapy for Duchenne Muscular Dystrophy
Dystrophin bei Muskeldystrophie vom Typ Duchenne und Becker-Kiener
Dystrophin Dp71 and the Neuropathophysiology of Duchenne Muscular Dystrophy
Creation of Dystrophin Expressing Chimeric Cells of Myoblast Origin as a Novel Stem Cell Based Therapy for Duchenne Muscular Dystrophy
Cardiac Protection after Systemic Transplant of Dystrophin Expressing Chimeric (DEC) Cells to the mdx Mouse Model of Duchenne Muscular Dystrophy
Dystrophin Expressing Chimeric (DEC) Cell Therapy for Duchenne Muscular Dystrophy: A First-in-Human Study with Minimum 6 Months Follow-up
Dual exon skipping in myostatin and dystrophin for Duchenne muscular dystrophy
Systemic delivery of full-length dystrophin in Duchenne muscular dystrophy mice
Dystrophin and mini-dystrophin quantification by mass spectrometry in skeletal muscle for gene therapy development in Duchenne muscular dystrophy
Adenine base editing-mediated exon skipping restores dystrophin in humanized Duchenne mouse model
Long-Term Protective Effect of Human Dystrophin Expressing Chimeric (DEC) Cell Therapy on Amelioration of Function of Cardiac, Respiratory and Skeletal Muscles in Duchenne Muscular Dystrophy
Deletion pattern in the dystrophin gene in Duchenne muscular dystrophy patients in northeast India
Dystrophin Expressing Chimeric (DEC) Human Cells Provide a Potential Therapy for Duchenne Muscular Dystrophy
Dystrophin bei Muskeldystrophie vom Typ Duchenne und Becker-Kiener
Dystrophin Dp71 and the Neuropathophysiology of Duchenne Muscular Dystrophy
Creation of Dystrophin Expressing Chimeric Cells of Myoblast Origin as a Novel Stem Cell Based Therapy for Duchenne Muscular Dystrophy
Cardiac Protection after Systemic Transplant of Dystrophin Expressing Chimeric (DEC) Cells to the mdx Mouse Model of Duchenne Muscular Dystrophy
Dystrophin Expressing Chimeric (DEC) Cell Therapy for Duchenne Muscular Dystrophy: A First-in-Human Study with Minimum 6 Months Follow-up
Dual exon skipping in myostatin and dystrophin for Duchenne muscular dystrophy
Systemic delivery of full-length dystrophin in Duchenne muscular dystrophy mice
Dystrophin and mini-dystrophin quantification by mass spectrometry in skeletal muscle for gene therapy development in Duchenne muscular dystrophy
Adenine base editing-mediated exon skipping restores dystrophin in humanized Duchenne mouse model
Long-Term Protective Effect of Human Dystrophin Expressing Chimeric (DEC) Cell Therapy on Amelioration of Function of Cardiac, Respiratory and Skeletal Muscles in Duchenne Muscular Dystrophy